Related Experiment Videos
Rapidly progressive IgA nephropathy
Naho Kobayashi1, Masashi Nishida2, Michiko Aoyama3
1Department of Pediatric Cardiology and Nephrology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kawaramachi-Hirokoji, Kamigyo-ku, 602-8566, Kyoto, Japan.
Indian Journal of Pediatrics
|April 6, 2017
Summary
A severe case of IgA nephropathy (IgAN) in a teen rapidly improved with corticosteroids. Despite initial side effects, treatment led to full renal function recovery, highlighting a remarkable clinical response.
Area of Science:
- Nephrology
- Immunology
Background:
- IgA nephropathy (IgAN) can present with rapid renal function decline.
- Crescentic IgAN indicates severe glomerular injury.
- Treatment responses in severe IgAN can vary.
Purpose of the Study:
- To report a unique case of severe crescentic IgA nephropathy in a adolescent.
- To describe the clinical course and treatment response in this remarkable case.
- To highlight the efficacy of corticosteroid therapy in severe IgAN.
Main Methods:
- Case presentation of a 14-year-old male with macroscopic hematuria and acute kidney injury.
- Diagnosis confirmed by percutaneous renal biopsy showing severe crescentic IgA nephropathy (88% crescents).
- Treatment initiated with high-dose intravenous pulse methylprednisolone followed by oral corticosteroids.
Main Results:
- Initial treatment with methylprednisolone caused transient worsening of renal function (increased BUN and creatinine) and side effects (nausea, malaise).
- Subsequent oral corticosteroid administration led to rapid and complete recovery of renal function.
- The patient experienced a remarkable clinical improvement despite the initial severe presentation.
Conclusions:
- Severe crescentic IgA nephropathy can be effectively treated with corticosteroids.
- Corticosteroid therapy, despite potential initial adverse effects, can lead to full renal recovery in IgAN.
- This case underscores the importance of timely and aggressive immunosuppressive treatment in severe IgAN.